()
 
 

Overview

La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed potential small molecule drug candidates to treat various other autoimmune and inflammatory conditions. The Company's common stock is traded on The NASDAQ Global Market under the symbol LJPC. More information about the Company is available on its Web site: http://www.ljpc.com.


Contact Information

6455 Nancy Ridge Drive
San Diego, CA 92121

tel: 858-452-6600
fax: 858-452-6893
http://www.ljpc.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $73.7M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.